$ cat ./records/who-approves-r21-malaria-vaccine-the-second-ever-backed-by-gates--2023.txt
WHO approves R21 malaria vaccine — the second ever — backed by Gates Foundation funding
[RECORD.TXT] · cat --full
The World Health Organization approved the R21/Matrix-M malaria vaccine developed with significant Gates Foundation support — the second malaria vaccine ever approved. R21 demonstrated 75% efficacy in trials, meeting WHO targets. Gates called it 'a great day for global health.' The vaccine is expected to dramatically reduce deaths from malaria, which kills over 600,000 people annually, the vast majority children under five in Sub-Saharan Africa.
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Gates Foundation funds anti-tick mRNA vaccine research to block Lyme disease transmission
Next →
Signs COP28 nuclear energy declaration alongside 20 nations
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.